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Cerebral cavernous malformations (CCMs) are hamartomatous vascular malformations characterized by abnormally
enlarged capillary cavities without intervening brain parenchyma. They cause seizures and cerebral hemorrhages,
which can result in focal neurological deficits. Three CCM loci have been mapped, and loss-of-function mutations
were identified in the KRIT1 (CCM1) and MGC4607 (CCM2) genes. We report herein the identification of PDCD10
(programmed cell death 10) as the CCM3 gene. The CCM3 locus has been previously mapped to 3q26-27 within
a 22-cM interval that is bracketed by D3S1763 and D3S1262. We hypothesized that genomic deletions might occur
at the CCM3 locus, as reported previously to occur at the CCM2 locus. Through high-density microsatellite
genotyping of 20 families, we identified, in one family, null alleles that resulted from a deletion within a 4-Mb
interval flanked by markers D3S3668 and D3S1614. This de novo deletion encompassed D3S1763, which strongly
suggests that the CCM3 gene lies within a 970-kb region bracketed by D3S1763 and D3S1614. Six additional
distinct deleterious mutations within PDCD10, one of the five known genes mapped within this interval, were
identified in seven families. Three of these mutations were nonsense mutations, and two led to an aberrant splicing
of exon 9, with a frameshift and a longer open reading frame within exon 10. The last of the six mutations led
to an aberrant splicing of exon 5, without frameshift. Three of these mutations occurred de novo. All of them
cosegregated with the disease in the families and were not observed in 200 control chromosomes. PDCD10, also
called “TFAR15,” had been initially identified through a screening for genes differentially expressed during the
induction of apoptosis in the TF-1 premyeloid cell line. It is highly conserved in both vertebrates and invertebrates.
Its implication in cerebral cavernous malformations strongly suggests that it is a new player in vascular morpho-
genesis and/or remodeling.
Introduction
Cerebral cavernous malformations (CCMs [MIM
116860]) are vascular malformations, mostly located
within the CNS. They are characterized by abnormally
enlarged capillary cavities without intervening brain pa-
renchyma (Russel and Rubinstein 1989). The most com-
mon symptoms are seizures and neurological deficits that
result from focal hemorrhages (Rigamonti et al. 1988;
Labauge et al. 1998). The prevalence of this condition
has been estimated to be 0.1%–0.5% (Otten et al. 1989).
Cavernous angiomas can occur in a sporadic or au-
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tosomal dominant inherited form. The proportion of fa-
milial cases has been estimated as high as 50% in His-
panic American patients with CCMs (Rigamonti et al.
1988) and close to 10%–20% in white patients (E. Tour-
nier-Lasserve, unpublished data). Familial cases are char-
acterized by the presence of multiple lesions, whereas
sporadic cases usually harbor only one CCM lesion (Ri-
gamonti et al. 1988; Labauge et al. 1998). Clinical pen-
etrance is incomplete, and it has been suggested that it
might depend on the CCM locus involved (Craig et al.
1998; Denier et al. 2004).
Three CCM loci have been previously mapped to 7q
(CCM1), 7p (CCM2), and 3q (CCM3), with 40% of
kindreds with CCMs being linked to CCM1, 20%
linked to CCM2, and 40% linked to CCM3 (Dubovsky
et al. 1995; Craig et al. 1998). Two CCM genes have
been identified so far—KRIT1 (CCM1) and MGC4607
(CCM2)—and the nature of their mutations in patients
with CCMs strongly suggests a loss of function in both
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cases (Laberge-le Couteulx et al. 1999; Sahoo et al. 1999;
Liquori et al. 2003; Denier et al. 2004).
Krit1 was initially identified as a rap1A-interact-
ing protein (Serebriiskii et al. 1997). Subsequently, its
N-terminal part, which contains an NPXY motif, was
shown to strongly interact with icap1a, a phosphopro-
tein that binds to the intracytoplasmic tail of integrin
b1 (Zhang et al. 2001; Zawistowski et al. 2002). Given
the multiple roles of integrins in processes such as cell
differentiation, proliferation, and/or apoptosis, as well
as their implications in angiogenesis, these data suggest
that Krit1 might play a role in integrin signaling path-
ways during vessel morphogenesis. Krit1 transcripts
have been detected in neural and epithelial cells during
development, and the Krit1 protein has been detected
in various cells, including neurons, glial cells, and en-
dothelial cells, and was reported to be associated with
microtubules (Denier et al. 2002; Gunel et al. 2002;
Guzeloglu-Kayisli et al. 2004). A recent invalidation of
this gene in the mouse has shown that Krit1 is not
required for vasculogenesis but is needed for arterial
morphogenesis and identity (Whitehead et al. 2004).
However, the early E11 embryonic lethality observed in
these invalidated embryos hampered the investigations
needed to explore the mechanisms that lead from Krit1
loss to CCM lesions. With regard to MGC4607, noth-
ing is known about the function of this protein, except
that it contains a phosphotyrosin-binding domain and
is involved in osmolarity sensing (Uhlik et al. 2003).
The CCM3 gene had been previously mapped to a
22-cM interval bracketed by D3S1763 and D3S1262.
We did not have access to any large family for which
linkage analysis could be performed to reduce the size
of this genetic interval. In the absence of any strong
candidate gene within this large interval, we chose to
use another strategy to reduce the size of the region of
interest. We hypothesized that deletions might be in-
volved in this condition, as has been reported elsewhere
for other hamartomatous conditions, such as tuberous
sclerosis, neurofibromatosis, or CCM2 cavernous an-
giomas (Viskochil et al. 1990; European Chromosome
16 Tuberous Sclerosis Consortium 1993; Trofatter et al.
1993; Denier et al. 2004). We performed a high-density
microsatellite genotyping of this 22-cM interval to
search for putative null alleles in 20 small but poten-
tially informative families with CCMs. In one patient,
we identified a de novo deletion within a 4-Mb interval
flanked by markers D3S3668 and D3S1614. This de-
letion encompassed D3S1763, the centromeric bound-
ary of the CCM3 interval, which strongly suggests that
the CCM3 gene lies within a 970-kb interval bracketed
by D3S1763 and D3S1614. In seven families, we iden-
tified deleterious mutations within the programmed cell
death 10 gene (PDCD10), one of the five known genes
that have been mapped to this interval. These data es-
tablish PDCD10, a gene highly conserved in vertebrates
and invertebrates, as a new player in vessel development
and/or maturation.
Material and Methods
Patients and Families
Twenty unrelated families were enrolled in this study,
on the basis of three criteria: (1) each proband had at
least one affected relative and/or had multiple cerebral
cavernous angiomas; (2) the families of these probands
were potentially informative for a study designed to detect
genomic deletions, on the basis of the identification of
microsatellite null alleles; and (3) molecular screening for
KRIT1 and MGC4607 point mutations was negative.
CCM diagnosis was based on cerebral magnetic reso-
nance imaging (MRI) features and/or pathological anal-
ysis. We considered as “affected” all individuals who
showed cavernous angiomas on cerebral MRI, whatever
their clinical status. We considered as “healthy” all in-
dividuals with normal MRI results. Those who did not
undergo MRI were classified as “unknown” (fig. 1).
DNA and RNA Extraction
Genomic DNA from probands and consenting rela-
tives was extracted from peripheral blood by use of stan-
dard procedures. Genomic DNA from 100 unrelated,
healthy, white French individuals was available as a con-
trol group. Total RNA was extracted from lympho-
blastoid Epstein-Barr virus (EBV) cell lines for 17 of the
20 probands (lymphoblastoid cell lines were not avail-
able for probands C064, C077, and C114), and cDNA
was prepared in accordance with standard procedures.
Genetic Markers
For the initial microsatellite screening, we used a panel
of 18 microsatellite markers that spanned the CCM3
interval (D3S1763–D3S1262) and the immediate cen-
tromeric and telomeric regions located on both sides of
this interval. The average distance between the markers
was !1 Mb. This panel included markers D3S1580,
D3S3686, D3S1262, D3S3592, D3S3583, D3S3609,
D3S3730, D3S3715, D3S3676, D3S3520, D3S3725,
D3S3053, D3S1574, D3S1282, D3S1614, D3S3622,
D3S1264, and D3S3673 (in qterrcen orientation) (figs.
2 and 3A).
Additional markers were used to define the bounda-
ries of the de novo deletion identified in family C052,
including D3S3682, D3S3668, D3S1268, D3S3689,
and new CA-repeat markers identified through screening
for dinucleotide tracks of ad hoc genomic sequences
that spanned the D3S3668–D3S1614 interval. Seven
new CA-repeat markers were identified and were de-
signated CA-AC092965a and CA-AC092965b (BAC
Figure 1 Genealogical trees of the 20 families with CCMs. Family numbers are indicated above each pedigree. Black symbols show
affected individuals; question marks indicate unknown status; empty symbols depict healthy individuals with normal MRI results. Probands
are designated by an arrow. Identified mutations have been indicated above the corresponding pedigrees.
Bergametti et al.: PDCD10 Is the CCM3 Gene 45
Figure 2 Parental noncontribution within family C052 at the
CCM3 locus. The genealogical tree for family C052, with CCM3 hap-
lotypes, is shown. A null allele was detected at the D3S3673, D3S1264,
and D3S3622 markers (boxed), which strongly suggested the existence
of a deletion; this deletion was confirmed by additional genotyping
(fig. 3).
AC092965/nt 61196–61235 and nt 130628–130667),
CA-AC072046 (BAC AC072046/nt 26097–26140),
CA-AC104629a and CA-AC104629b (BAC 104629/nt
92952–92991 and nt 148355–148394), CA-AC108675
(BAC AC108675/nt 59576–59615), and CA-AC013458
(BAC AC013458/nt 38576–38617) (fig. 3A and 3B) (see
the National Center for Biotechnology Information
[NCBI] Web site).
PDCD10 Mutation Screening
Genomic DNA of all probands was amplified using
10 sets of primers designed to amplify each of the coding
exons (exons 4–10), the 5′ noncoding exons, and the
flanking splice sites and was analyzed by direct sequenc-
ing on an ABI 3100 (PE Applied Biosystems) (table 1).
cDNA from all probands (except probands C064, C077,
and C114, from whom no cDNA was available) was
amplified using a set of two primers to amplify an 802-
bp fragment that spanned exons 4–10 (table 1). Am-
plicons were checked on agarose gels and were se-
quenced on an ABI 3100 (PE Applied Biosystems).
Multiple-Tissue Northern (MTN) Blot
An 802-bp cDNA probe that contained exons 4–10
was generated from a lymphoblastoid EBV cell line de-
rived from a normal healthy control (fragment 4–10 [ta-
ble 1]) and was cloned in the pGEM-T Easy Vector Sys-
tem (Promega). The probe sequence was identical to the
reported human sequence. One hundred nanograms of
the full-length cDNA fragment were radiolabeled with
[32P]-dCTP and were used to hybridize a human adult
MTN blot (Human 12-lane MTN Blot [Clontech]) in
ExpressHyb solution (Clontech) at 1–2 # 106 cpm/ml,
in accordance with manufacturer instructions. Kodak
film was exposed to the blot at 80C for 17 h for
PDCD10 and for 6 h for the control b-actin probe
(Clontech).
Results
De Novo Deletion in Family C052
None of the families available in this study was large
enough to allow us to reduce the size of the CCM3
interval through genetic linkage analysis and identifi-
cation of recombinants. We hypothesized that deletions
might be involved in CCM, so we searched with 18 mi-
crosatellite markers for putative null alleles in 20 un-
related families. We did not detect any abnormality, ex-
cept in family C052, in whom apparent non-Mendelian
inheritance was observed for three contiguous mark-
ers—D3S3673, D3S1264, and D3S3622—located at the
centromeric boundary of the CCM3 interval (fig. 2).
Patient III1 in that family appeared homozygous and
failed to inherit an allele from her heterozygous unaf-
fected father for all three markers. The same family did
not exhibit incompatible genotypes with other markers,
which thus eliminated inaccurate paternity information
and sampling error as sources of incompatibility. Indi-
vidual III1 was heterozygous at D3S1614 and D3S3668
and compatible with her father. Analysis of family C052
with the use of additional microsatellites located cen-
tromeric to D3S1614 detected null alleles at D3S3682
and CA-AC092965b (fig. 3), whereas genotypes of in-
dividual III1 for other centromeric markers, including
AC072046, AC104629, AC108675, AC013458, and
D3S3668, were heterozygous and compatible with the
family structure. These data were consistent with a de-
letion of a maximum size of 1.9 Mb within an interval
flanked by markers D3S1614 (telomeric boundary) and
CA-072046 (centromeric boundary). Its minimum size
was estimated at 1.1 Mb. This deletion encompassed
D3S1763, the previously defined CCM3 centromeric
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Table 1
PCR Primers Used for Mutation Detection in the PDCD10 Gene
EXON(S)
OLIGONUCLEOTIDE SEQUENCE
PRODUCT
SIZE
(bp)Forward Reverse
1a GAGTCCCCATAAGCCTCT TTCCTCCTCCCTTTTCTCT 552
2a CCCCTGCTTTGTAAGTAAGA TAATCCCTCGGTTTCCTC 300
3a AAAACTGGAAATGGAAGACA ATTGCTTGGACCTGGAAG 453
4a CCAACTAGGTTTGCTTTCAC GCACCGATAAGAGTTCATTC 478
5a CTCAGAAATGTGCTTTTTCC AACAGGCATAAGATGGCTAA 238
6a TCATGACACCTGCTTTACAA ACAGTAGGGAAGGAAGATCC 359
7a GCTAATGAATTCTGCTTTGC GAAACCAAACGCCATAAAGT 441
8a GAAGTGATTGCGCTTAACAT CAACTAGGCATAAACCAACATC 280
9a TAAAGTGCATCCCATATCCT TGGCTAGATTAGCAACCATT 358
10a ATTACCAGTCAGAACCACCA CCTTCAGGAGGGACTGATA 400
4–10b GTGAATGAAGATTCCTCTGC CCTTCAGGAGGGACTGATA 802
a Genomic DNA amplification was performed for this exon with the use of PCR primers;
mutation detection was done by direct sequencing. Coding exons include exons 4–10.
b cDNA studies were performed for these exons by the use of RT-PCR primers.
boundary, which strongly suggested that the critical in-
terval that contained the gene spanned 970 kb and was
bracketed by D3S1763 and D3S1614.
PDCD10 Point Mutations
Five known or putative genes have been mapped within
this critical interval: FLJ33620, PDCD10, SERPINI1,
GOLPH4, and LOC389174 (see the NCBI Web site). We
designed sets of primers to amplify genomic DNA and
cDNA for each of those genes. On the basis of its putative
role in apoptosis, PDCD10 was selected as the first gene
for screening (Wang et al. 1999).
Genomic DNA sequence analysis identified five dele-
terious mutations in six of the probands, including three
direct nonsense mutations and two splice-site mutations
that lead to a frameshift. The probands from families
C030 and C077 harbored the same mutation (nt
586CrT, stop codon at codon 196); haplotype analysis
did not favor any founder effect in these two families
(data not shown). The C031 proband had a mutation
in exon 7 (nt 385CrT, stop codon at codon 129), and
the C055 proband had a mutation in exon 5 (nt 103
CrT, stop codon at codon 35). The C107 proband had
a splice-site mutation in intron 8 (nt 475-1GrA). A de-
letion of one of the two AAGT short repeats located
between exon 9 and IVS9 was detected in the C044
proband (table 2; fig. 4A and 4B). Agarose gel electro-
phoresis of amplified cDNA revealed abnormal tran-
scripts in the C107 and C044 probands. Sequence anal-
ysis of the cDNA of these probands showed an abnormal
splicing of exon 9, leading to a frameshift and a change
in the position of the stop codon (TGA, nt 637–639/
TGA, nt 681–683).
In addition, cDNA analysis showed an abnormal tran-
script in which exon 5 was abnormally spliced in the
C043 proband. No genomic mutation was detected at
consensus splice sites in this patient. This abnormal tran-
script was detected neither in any of our controls nor
in the 1150 ESTs reported so far in databases, which
strongly suggests that this abnormal transcript is path-
ogenic and might be due to an as-yet undetected intronic
mutation that affects splicing or to a deletion of the
genomic region that encompasses exon 5.
Combined haplotype and mutation screening of rel-
atives of these probands showed that three of these mu-
tations occurred de novo in the probands of pedigrees
C044, C052, and C107. Within pedigrees C030, C031,
C043, C055, and C077, the mutation cosegregated with
the affected phenotype. None of the identified mutations
was detected in the panel of 200 control chromosomes.
In summary, a total of eight different mutations, in-
cluding one large deletion, have been observed in this
panel of 20 families with CCMs. Interestingly, we did
not detect any exonic polymorphism of this gene in the
20 probands.
Structure of the PDCD10 Gene, cDNA, and Protein
PDCD10 cDNA (alias, “TFAR15”) was initially cloned
on the basis of its up-regulated expression in a human
myeloid cell line, TF-1, in which apoptosis has been in-
duced by deprivation of granulocyte macrophage colony–
stimulating factor (Wang et al. 1999). Its cDNA and ge-
nomic structures have been reported in several genome
databases with 1150 reported ESTs. It extends 150 kb
and includes seven coding exons and three 5′ noncoding
exons. Three alternative transcripts that differ only in
their 5′ UTRs have been identified for this gene (GenBank
accession numbers NM_007217, NM_145859, and
NM_145860). The ATG initiator codon is located in the
fourth exon.
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Table 2
PDCD10 Mutations
Pedigree Mutationa Location Effect on cDNA
C052 Deletion of the whole gene … …
C043 No genomic mutation detected … Exon 5 deletion
C055 c.103CrT Exon 5 Nonsense mutation at codon 35
C031 c.385CrT Exon 7 Nonsense mutation at codon 129
C107 c.475-1GrT IVS8 Exon 9 deletion, frameshift
C044 c.556_5572del4 Exon 9–IVS9 Exon 9 deletion, frameshift
C030 c.586CrT Exon 10 Nonsense mutation at codon 196
C077 c.586CrT Exon 10 Nonsense mutation at codon 196
a Numbering of PDCD10 nucleotides is in accordance with the full-lengh cDNA, beginning
nucleotide numbering at A of the ATG initiator codon.
The coding portion of the cDNA is 636 bp long and
encodes a 212-aa predicted protein. Database searches
did not identify any paralog but identified several strongly
conserved orthologs both in vertebrate and invertebrate
species, including Mus musculus (Pdcd10 [UniGene ac-
cession number Mm.316473], 98% identity at the protein
level), Danio rerio (zgc85629, 92% identity), Drosophila
melanogaster (CG5073, 49% identity), and Caenorhab-
ditis elegans (2K896, 39% identity). In addition, partial
homologous transcripts also have been reported for nu-
merous vertebrate and invertebrate species. Searches of
protein databases (ExPASy Proteomics Server) with the
coding sequence of Homo sapiens PDCD10 did not reveal
a signal peptide, transmembrane domain, or any known
functional domain.
PDCD10 mRNA Expression
Northern blot analysis showed ubiquitous expression,
in agreement with the expression pattern that can be
deduced from the multiple PDCD10 ESTs reported in
the dBEST database. A band of ∼1.35 kb was detected
in all tissues tested, although at a different level (fig. 5),
consistent with the 1.4-kb, 1.3-kb, and 1.2-kb sizes of
the three reported PDCD10 transcripts.
Discussion
We have identified PDCD10 as the gene that causes CCM
in families with CCM3, on the basis of the identification
of seven distinct mutations in eight unrelated families. The
nature of some of these mutations, particularly the de-
letion of the whole gene observed in family C052, strongly
suggests that one of the mechanisms that leads to cav-
ernous angiomas might be PDCD10 haploinsufficiency.
We detected a mutation in 8 of the 20 families in our
study. CCMs are genetically heterogeneous, and multi-
locus linkage data suggested that 40% of families with
CCMs are linked to the CCM3 locus (Craig et al. 1998).
Since the 20 families screened in this study were included
on the basis of a negative KRIT1 (CCM1) and MGC4607
(CCM2) mutation screening, a higher proportion of fam-
ilies with a PDCD10 mutation would have been ex-
pected. Several hypotheses can be raised to explain this
discrepancy. Some of these families might have a genomic
deletion within either PDCD10, KRIT1, or MGC4607,
which would not have been detected by the exon-by-exon
sequencing approach used to screen those three genes.
Another hypothesis could be the existence of additional,
as-yet unidentified exons within PDCD10. Although this
possibility cannot be excluded, there is no discrepancy
between the size of the reported cDNA and that of the
transcript seen in the northern blot. A third possibility is
somatic mosaicism of a de novo mutation in any of the
three CCM genes, which would be present at a low fre-
quency in leukocyte DNA, particularly in the families in
whom the proband is the only affected case. As has been
reported elsewhere with regard to other hamartomatous
conditions, this somatic mosaicism may render quite dif-
ficult the identification of the deleterious mutation (Ver-
hoef et al. 1999). Finally, we cannot exclude the possi-
bility of the existence of a fourth CCM gene that either
was missed in the multilocus linkage analysis or is located
in close proximity to one of the three CCM genes iden-
tified so far.
The identification of PDCD10 as the CCM3 gene
raises the question of its cellular function and its specific
role in angiogenesis and/or remodeling of cerebral vessels.
PDCD10/TFAR15 was initially identified as a gene up-
regulated in the TF-1 premyeloid cell line after growth-
factor deprivation and apoptosis induction (Wang et al.
1999). This gene was shown recently to be up-regulated,
in a study designed to identify apoptosis-related genes in
a fibroblast cell line exposed to specific apoptosis induc-
ers, such as staurosporine, cycloheximide, and TNF-a
(Busch et al. 2004). These preliminary data suggest that
this gene, which is highly conserved from nematode to
human, might play a role in apoptotic pathways. Inhi-
bition of the nematode PDCD10 ortholog, 2K896, leads
to embryonic lethality in 40% of the embryos and a
dumpy phenotype in postembryonic viable embryos (Ka-
math et al. 2003). However, the pathways and mecha-
nisms that lead to these phenotypes are unknown.
Figure 4 PDCD10 point mutations. A, PDCD10 genomic organization. The 10 PDCD10 exons are numbered and are indicated by
vertical hatches. The ATG initiator codon is included in the 4th exon, and the TGA stop codon is in the 10th (last) exon. The locations of the
different PDCD10 point mutations are indicated by arrows. B, Mutated alleles in families harboring mutations. Family numbers are given
above the mutation. Sequence chromatograms of genomic DNA are shown for all probands, except for the C043 proband, whose chromatogram
is of cDNA. Families C030 and C077 harbored the same mutation; therefore, we show only the chromatogram obtained in the proband of
pedigree C030. F p forward primer; R p reverse primer.
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Figure 5 PDCD10 northern blot analysis. Human adult MTN
(Human 12-lane MTN Blot [Clontech]) was hybridized with a
PDCD10 (upper panel) and b-actin (lower panel) human cDNA probe.
Lane 1, brain; lane 2, heart; lane 3, skeletal muscle; lane 4, colon;
lane 5, thymus; lane 6, spleen; lane 7, kidney; lane 8, liver; lane 9,
small intestine; lane 10, placenta; lane 11, lung; and lane 12, peripheral
blood leukocytes.
In summary, these data establish PDCD10, a protein
that has been related to apoptosis, as a new player in
vessel development and/or maturation. The putative role
of this protein in an apoptotic pathway that might be
involved in angiogenesis and the putative link of such a
pathway with either KRIT1 and/or MGC4607 remain to
be investigated.
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